American Regent recalls injectable epinephrine over particulate matter and leaking vials

American Regent is recalling a lot-group of injectable epinephrine after finding foreign particles in the vials and evidence that some were broken and leaking, according to the FDA's enforcement database [s1]. The agency has classified the action as Class I — its most serious recall category, used when a product could plausibly cause serious harm [s1].

The recall covers Epinephrine Injection, USP, 30 mg/30 mL (1 mg/mL), packaged as a 30 mL multiple-dose vial for intravenous infusion and for intramuscular and subcutaneous use [s1]. About 31,935 vials distributed nationwide are affected [s1]. The company began the recall on 11 August 2026 and notified customers by letter; the FDA recorded and classified it on 16 September, and its status is listed as ongoing [s1]. The affected lots are 25128L1C0 (expiry 31 August 2026), 25280L1C0 (expiry 31 October 2026) and 26108L1C0 (expiry 31 July 2027) [s1].

What was found

The stated reason for the recall is the "presence of particulate matter and lack of assurance of sterility" [s1]. The firm's investigation identified the particles as nylon, cellulosic material, acrylic, polyethylene and glass, and also found broken and leaking vials [s1]. That combination — visible foreign matter plus a breach in the container that protects a sterile drug — is why the classification is at the top of the scale rather than a lower tier.

Particulate matter in an injectable is not a cosmetic defect. A drug delivered straight into a vein bypasses every filter the body uses on things it swallows or breathes, so particles can lodge in small blood vessels and, in the worst case, trigger clots, inflammation or an immune reaction. Glass fragments and broken vials add a second hazard: a container that no longer guarantees sterility can admit microbes, and a contaminated intravenous drug is a direct route to bloodstream infection.

Why this product matters

This is not a consumer auto-injector but a hospital vial. The recalled 30 mL multiple-dose presentation is the kind of stock kept in pharmacies, operating theatres and critical-care units, where epinephrine is drawn up and diluted for infusion. In this concentration, the FDA-approved labelling for epinephrine injection describes its use to raise mean arterial blood pressure in adults whose blood pressure has collapsed from septic shock [s2]. Epinephrine of one form or another is also a front-line drug in cardiac arrest and severe allergic reactions, which is why a supply problem in a widely stocked vial draws attention beyond the single manufacturer.

A recall of an emergency medicine carries a particular tension. The drug is used in situations where seconds count and where there may be no time to inspect a vial for a faint haze of particles or a hairline crack. That is the scenario the Class I label is meant to flag to the people who stock and draw these vials.

What a recall does — and does not — mean

A Class I classification describes the potential severity of the defect, not a count of injuries; the enforcement record does not report that anyone has been harmed [s1]. It is also a voluntary, firm-initiated recall, meaning American Regent identified the problem and pulled the lots rather than being ordered to [s1]. That is the system working as intended: a manufacturer catching a container-integrity failure and removing the affected stock before more of it reaches patients.

For hospitals and pharmacies, the practical response to any recall of this kind is to check inventory against the listed lot numbers and quarantine matching stock, following the recalling firm's instructions [s1]. Individual patients rarely hold this presentation themselves, but anyone unsure whether a medicine they have is affected should ask their pharmacist rather than guess.

What to watch

The open questions are whether the recall expands to further lots, whether it strains supply of a drug that hospitals cannot do without, and what the root-cause investigation finds about how nylon, glass and other particles reached a sterile line [s1]. Container-integrity failures in sterile injectables have been a recurring theme in FDA enforcement, and the fixes tend to be in manufacturing process control rather than the molecule itself.

This article reports a regulatory action and is not medical advice. Questions about a specific medicine should go to a pharmacist or clinician.

Sources

• Enforcement Report: Epinephrine Injection, USP, 30 mg/30 mL — American Regent, Inc. (recall D-0865-2026, Class I) — U.S. Food and Drug Administration, classified 16 September 2026
• Epinephrine Injection, USP prescribing information: indication in septic shock — U.S. Food and Drug Administration